

Correlation of Oxacillinase Gene Carriage With the Genetic Fingerprints of Imipenem-Resistant Clinical Isolates of *Acinetobacter baumannii*

Zahra Zanganeh¹ and Fereshteh Eftekhari^{1,*}

¹Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University, Tehran, IR Iran

*Corresponding author: Fereshteh Eftekhari, Department of Microbiology, Faculty of Biological Sciences, Shahid Beheshti University G. C., Tehran, IR Iran. Tel: +98-2129903208, Fax: +98-2122431664, E-mail: Feftekhari@sbu.ac.ir

Received: January 5, 2015; Revised: May 3, 2015; Accepted: May 15, 2015

Background: Emergence of multidrug-resistant *Acinetobacter baumannii* has resulted in the treatment failure of related infections and an increase in patient mortality. The presence of class D β -lactamases (oxacillinases) in this organism is an important mechanism underlying resistance to beta-lactam antibiotics.

Objectives: The aim of this work was to investigate the correlation between oxacillinase gene carriage and genetic fingerprints in imipenem-resistant burn and non-burn isolates of *A. baumannii*.

Materials and Methods: Fifty-eight *A. baumannii* isolates were collected from October 2011 to April 2012, which included 28 burn isolates from Shahid Motehari Hospital and 30 non-burn isolates from Imam Hossein Hospital. The minimum inhibitory and minimum bactericidal concentrations (MIC and MBC) of imipenem were measured by the broth microdilution method. The presence of oxacillinase genes (OXA-23-, OXA-24-, OXA-51-, and OXA-58-like genes) was shown using type-specific primers and PCR. Genetic profiles were generated by RAPD-PCR fingerprinting.

Results: OXA-23 was observed in 81% of the isolates and its distribution was similar within the two groups. The presence of OXA-51 was shown in 58.6% of the isolates, of which most were burn isolates (67.6%). OXA-24 was present in 20.7% of the isolates, all belonging to the burn group; OXA-58 was not observed in any of the isolates. RAPD-PCR fingerprints revealed two clusters at a similarity level of 70% (A, B). At a similarity level of 85%, nine different groups were observed for burn and non-burn isolates.

Conclusions: Our results showed that *bla*_{OXA-23} was the most prevalent gene, followed by *bla*_{OXA-51}, among the burn and non-burn clinical isolates of *A. baumannii*. *Bla*_{OXA-24}-like genes were detected at a lower level and were only found among the burn isolates, which also showed higher heterogeneity compared to the non-burn group.

Keywords: PCR, RAPD-PCR; *Acinetobacter baumannii*

1. Background

Emergence and spread of multidrug-resistant (MDR) *Acinetobacter baumannii* in nosocomial settings has become a serious concern in clinical practice. The organism commonly targets critically ill patients in intensive care units (ICU) and burn wards (1). The infections caused by this organism include bacteremia, ventilator-associated pneumonia, meningitis, and infections of the urinary tract, wounds, and burns (1, 2). *Acinetobacter baumannii* exhibits a variety of resistance mechanisms to all existing antibiotic classes, including active drug efflux, modification of drug target sites, and most importantly, enzymatic inactivation of the antimicrobial agents (2, 3). Carbapenems, especially imipenem, is often used as the drug of choice for treatment of *A. baumannii* infections. However recently, high levels of resistance have emerged, causing treatment failure (4, 5). The most common mechanism responsible for carbapenem resistance in *A. baumannii* is production of carbapenemases, including metallo- β -lactamases (MBLs) and class D β -lactamases (oxacillinases) which, class D β -lactamases have been reported as the most widespread carbapenemases in *A. baumannii* isolates (2, 5-8).

The first oxacillinase found in *A. baumannii* was observed in an imipenem-resistant strain in Scotland in 1985, which was later designated as OXA-23. Today, over 220 OXA-type enzymes have been reported (9). Among these, five main phylogenetic subgroups have been recognized in imipenem-resistant *A. baumannii*, including OXA-23-, OXA-24/40-, OXA-51-, OXA-58-, and more recently, OXA-143-like oxacillinases (10). The largest subgroup is the chromosomally encoded OXA-51, followed by OXA-23-like enzymes (10, 11). However, plasmid-mediated OXA-51 genes have also been reported (12). *bla*_{OXA-23}- and *bla*_{OXA-24/40}-like genes can be chromosomal or plasmid-mediated, whereas *bla*_{OXA-58}-like genes are mostly plasmid-mediated (11). Rapid development of MDR strains, mostly owing to the horizontal transfer of antibiotic determinants among the isolates, makes it imperative to identify the underlying resistance mechanisms and study the epidemiology of these infections. Among the fingerprinting methods used, randomly amplified polymorphic DNA (RAPD) has been widely used to detect polymorphisms in many organisms, including *A. baumannii*.

2. Objectives

The objective of this study was to compare the presence of *bla*_{OXA-23}, *bla*_{OXA-24/40}, *bla*_{OXA-51}, and *bla*_{OXA-58}-like genes in two groups of burn and non-burn clinical isolates of *A. baumannii* and study the clonal spread and heterogeneity of the isolates.

3. Materials and Methods

3.1. Bacterial Isolates

Fifty-eight *A. baumannii* isolates were collected from Imam Hossein (30 non-burn) and Shahid Motahari (28 burn) Hospitals from October 2011 to April 2012 in Tehran. Table 1 shows the distribution of different specimen types among burn and non-burn clinical isolates of *A. baumannii*. Phenotypic identification of the isolates was confirmed by standard biochemical tests; the isolates were maintained in brain heart infusion broth (Oxoid, UK) containing 10% dimethyl sulfoxide (v/v) at -20°C.

3.2. Imipenem Susceptibility Testing

The MIC and MBC of imipenem (Moon Chemicals, China) were determined by broth microdilution, according to the guidelines recommended by the Clinical and Laboratory Standards Institute (13).

3.3. Detection of OXA-Like Genes by PCR

DNA extraction was carried out by boiling. Briefly, a loopful of an overnight grown culture of each test isolate

was suspended in 500 µL of sterile double-distilled water, boiled at 100°C for 10 min, and centrifuged at 13,000 × g for 10 minutes. The supernatant was then used as the DNA template for PCR amplification. *bla*_{OXA-23}, *bla*_{OXA-24}, *bla*_{OXA-51}, and *bla*_{OXA-58}-like genes were detected by PCR using the primers listed in Table 2 (14). PCR reaction mixtures (25 µL) contained 1 µL of DNA template, 1.4 mM MgCl₂, 0.2 mM each dNTP, 0.4 µM primer, and 0.625 U of Taq DNA polymerase in the buffer provided by the manufacturer (CinnaGen, Iran). The amplifications were performed in a thermocycler (Techne TC-3000G; UK), with the following program: initial denaturation at 94°C for 5 minutes, 33 cycles of 94°C for 25 seconds, 53°C for 40 seconds, and 72°C for 50 seconds, followed by a final elongation step at 72°C for 6 minutes (11). *A. baumannii* NCTC 13304 harboring *bla*_{OXA-23} and *A. baumannii* NCTC 12156 carrying *bla*_{OXA-51} were used as controls (15). PCR products were separated on 1% agarose gels and observed after staining with RedSafe (iNtRON Biotechnology, Korea) using an image analysis system (UVLtec; St John's Innovation Centre, UK).

3.4. Generation of DNA Fingerprints by RAPD-PCR

PCR reaction mixtures (25 µL) contained 2 µL of template DNA, 0.5 mM each dNTP, 4 mM MgCl₂, 1.5 U of Taq polymerase, and 1 µM DAF4 primer (5'-CGGCAGCGCC-3') in the buffer provided by the manufacturer (CinnaGen, Iran) (16). Amplifications were performed in a thermal cycler (Techne TC-3000G, UK) using the following program: denaturation at 94°C for 2 minutes followed by 45 cycles of denaturation at 94°C for 40 seconds, annealing at 48°C for 1 minute, and extension at 72°C for 40 seconds, with a final extension period of 5 minutes at 72°C. The PCR

Table 1. Distribution of Different Specimen Types among Burn and Non-Burn Clinical Isolates of *Acinetobacter baumannii*^a

Isolate Group	Number of Isolates in Each Specimen Type					
	Wound	Sputum	Blood	Catheter	CSF	Trachea
Burn	25	3	0	0	0	0
Non-burn	3	16	5	3	2	1

^a Abbreviation: CSF, cerebral spinal fluid.

Table 2. Primers Used for Detection of OXA-Like Genes

Primer	Sequence	Product Size, bp
OXA-23		501
Forward	5'-GATCGGATTGGAGAACCAGA-3'	
Reverse	5'-ATTTCTGACCGCATTTCAT-3'	
OXA-24		246
Forward	5'-GGTTAGTTGGCCCCCTTAAA-3'	
Reverse	5'-AGTTGAGCGAAAAGGGGATT-3'	
OXA-51		353
Forward	5'-TAATGCTTTGATCGGCCTTG-3'	
Reverse	5'-TGGATTGCACCTCATCTTGG-3'	
OXA-58		599
Forward	5'-AAGTATTGGGGCTTGTGCTG-3'	
Reverse	5'-CCCTCTGCGCTCTACATAC-3'	

products were separated on 1.2% agarose gels, stained, and visualized as described above.

3.5. Statistical Analyses

Chi-square analysis was employed for the comparison of OXA gene carriage between the two groups of isolates using the SPSS version 21. Dendrograms for RAPD fingerprints were generated based on the band-matching coefficient of Dice, SAHN, and clustering in the unweighted pair group method with arithmetic averages (NTSYS-pc version 2.02; Exeter Software, Setauket, NY, USA).

4. Results

All isolates were resistant to imipenem with MIC and MBC values of $> 32 \mu\text{g/mL}$. However, these values for non-burn isolates ranged from 32 to 128 $\mu\text{g/mL}$, whereas the burn isolates had MIC and MBC values of $> 128 - 1012 \mu\text{g/mL}$, indicating even higher levels of resistance. The results of PCR amplifications (Figure 1) showed that *bla*_{OXA-23} was present in 47 isolates (81%), which was not significantly different between the two groups (78.6% burn vs. 83.3% non-burn). The presence of *bla*_{OXA-51} was shown in 34 isolates (58.6%), of which most were burn isolates (82.1% vs. 36.6%, $P < 0.05$). Interestingly, *bla*_{OXA-24} was found in 12 isolates (20.7%), all belonging to the burn group, and none of the isolates harbored *bla*_{OXA-58} (Figure 1). Overall, among the non-burn group, 16 isolates (53.3%) carried *bla*_{OXA-23} and two (6.7%) harbored *bla*_{OXA-51} alone, nine (30%) had both genes, and three did not carry any of the tested OXA genes. On the other hand, OXA-like genes were more widely distributed among the burn isolates, where one (3.6%), two (7.2%), and three (10.6%) isolates carried *bla*_{OXA-23}, *bla*_{OXA-24}, and *bla*_{OXA-51} alone, respectively. Twelve burn strains had both *bla*_{OXA-23} and *bla*_{OXA-51} (42.8%), two carried *bla*_{OXA-23}/*bla*_{OXA-24} (7.2%), one harbored *bla*_{OXA-24}/*bla*_{OXA-51} (3.6%), and seven isolates had all three OXA-like genes (25%). These results show a higher rate of multiple OXA gene carriage among the burn isolates and correlate with the higher imipenem MIC and MBC values obtained for the burn isolates.

Figure 2 presents the RAPD fingerprints of *A. baumannii* isolates. Analysis of these fingerprints revealed two clusters (A and B) at a similarity level of 70% and nine groups at a similarity level of 85% (Figure 3). Table 3 shows the distribution of RAPD fingerprints among burn and non-burn isolates. Most of the burn isolates ($n = 18$, 64.3%) were placed in cluster B, of which, seven, eight, and three belonged to the groups B7, B8, and B9, respectively. Of the 10 burn isolates in cluster A, four, five, and one isolate were placed in the groups A3, A4, and A5, respectively (Table 3). Most of the non-burn strains belonged to cluster A ($n = 21$, 70%), of which majority ($n = 16$, 76.2%) were in the group A1 and the remaining five were found in groups A2 ($n = 1$), A3 and A4 ($n = 2$ each). The non-burn strains placed in cluster B were found in groups B6 and B7 ($n = 4$ each), and B8 ($n = 1$). These results suggest the clonal spread of *A. baumannii*

in the clinical isolates from the two hospitals. However, a higher degree of heterogeneity was observed among the burn isolates compared to the non-burn isolates.






Figure 1. Distribution of Oxacillinase Genes in Imipenem-Resistant Burn and Non-Burn Isolates of *Acinetobacter baumannii*

Figure 2. RAPD-PCR Finger Prints of *Acinetobacter baumannii* Clinical Isolates



M, 100-bp DNA molecular weight marker, profiles 37 - 42 show the DNA fingerprints of non-burn isolates; 43 - 51 represent the DNA profiles of burn isolates.

Figure 3. Clonal Distribution of *Acinetobacter baumannii* Burn and Non-Burn Isolates Using RAPD-PCR Fingerprints at a Similarity Level of 85%



A dendrogram was generated based on the band-matching coefficient of Dice, SAHN, and clustering in the unweighted pair group method with arithmetic averages.

Table 3. Distribution of RAPD-PCR Fingerprints among Burn and Non-Burn Cluster B (No. of Isolates)

Isolate Group	Cluster A (No. of Isolates)					Cluster B (No. of Isolates)					
	70% ^a		85% ^a			70% ^a		85% ^a			
	A ₁	A ₂	A ₃	A ₄	A ₅	B ₆	B ₇	B ₈	B ₉		
Burn	10	-	-	4	5	1	18	-	7	8	3
Non-Burn	21	16	16	2	2	-	9	4	4	-	1

^a level of similarity.

5. Discussion

Nosocomial outbreaks of oxacillinase-producing *A. baumannii* have been reported worldwide. Among the five main phylogenetic subgroups, the chromosomally located *bla*_{OXA-51}-like gene has been used as a species-specific marker for the identification of *A. baumannii* (16-18). However, plasmid-mediated OXA-51 has also been detected in *A. baumannii* isolates (12). In addition, “non-*baumannii*” species of *Acinetobacter* have been shown to harbor *bla*_{OXA-51} (19). In the present study, 58.6% of the *A. baumannii* clinical isolates harbored *bla*_{OXA-51}, majority of which were burn isolates. The prevalence of *bla*_{OXA-51} in the clinical isolates of *A. baumannii* was reported as 77.8% in Turkey and 85.3% in South Africa (20, 21). Iranian studies have mostly used the presence of *bla*_{OXA-51} as a tool to identify *A. baumannii* and have shown 100% carriage of the gene (18, 22, 23). The presence of *bla*_{OXA-51} does not correlate with the level of carbapenem resistance because the gene is regulated by the insertion sequence ISAb_{a1}; this indicates that resistance to carbapenems cannot be inferred solely from the detection of *bla*_{OXA-51}-like genes (24). In contrast, genes encoding OXA-23, OXA-24, and OXA-58 enzymes are consistently associated with resistance or reduced susceptibility to imipenem (24). Among oxacillinases, OXA-23 has been shown as the most prevalent gene in *Acinetobacter* spp. worldwide, followed by *bla*_{OXA-51} (11, 25, 26). As found in the present study, several studies from Iran have found *bla*_{OXA-23} to be the most prevalent oxacillinase gene, and found much lower rates of *bla*_{OXA-24} and *bla*_{OXA-58} occurrence among *A. baumannii* clinical isolates (18, 23, 27).

Coexistence of multiple OXA genes has been reported in many studies. Feizabadi et al. showed that 25% and 17.9% of MDR *A. baumannii* carried *bla*_{OXA-51}/*bla*_{OXA-23} and *bla*_{OXA-51}/*bla*_{OXA-24}, respectively (18). A study from Poland compared OXA gene carriage between burn and ICU isolates and found that *bla*_{OXA-51}/*bla*_{OXA-24} genes were dominant in the ICU group and *bla*_{OXA-51}/*bla*_{OXA-23}-like genes were dominant among the burn isolates (28). Our results showed that only 30% of the non-burn isolates carried *bla*_{OXA-23}/*bla*_{OXA-51}, while 78.6% of the burn isolates harbored two to three oxacillinase genes.

Our RAPD-PCR results showed clear differences between the distribution of OXA genes in the two groups of isolates; higher heterogeneity was observed among the

burn strains (Table 2). Sadeghifard et al. showed 6 RAPD-PCR patterns among *Acinetobacter* spp. isolates in Tehran and found distinguishable fingerprints for *A. baumannii* strains compared to the non-*A. baumannii* isolates (29). Popova et al. used RAPD-PCR to type 130 MDR *A. baumannii* strains and showed that all strains grouped into two clusters (A and B), of which 82% were in the two dominant groups (30). We also found two clusters among which the RAPD fingerprints of both groups of isolates were distributed. However, most of the burn isolates (64.3%) were placed in one cluster (B). Conversely, 70% of the non-burn isolates were placed in the second cluster (A). In addition, there was much higher heterogeneity among the burn isolates at a similarity level of 85%, compared to that among the non-burn isolates (Table 2). These results show the limited lineage of infection-causing *A. baumannii* isolates in hospital environments. The heterogeneity, when detected, would most probably be attributed to the horizontal transfer of genetic elements such as plasmids among individual isolates.

Acknowledgements

The authors wish to thank the Shahid Beheshti university research council for the financial support extended to this research.

Authors' Contributions

Study concept and design: Eftekhar. Analysis and interpretation of data: Eftekhar and Zanganeh. Drafting of the manuscript: Zanganeh and Eftekhar. Critical revision of the manuscript for important intellectual content: Eftekhar. Statistical analysis: Zanganeh. Study supervision: Eftekhar.

Funding/Support

This research was financially supported by the Shahid Beheshti university research council.

References

1. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21(3):538-82.
2. Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology,

- antimicrobial resistance, and treatment options. *Clin Infect Dis*. 2008;**46**(8):1254-63.
3. Manchanda V, Sanchaita S, Singh N. Multidrug resistant acinetobacter. *J Glob Infect Dis*. 2010;**2**(3):291-304.
 4. Amudhan SM, Sekar U, Arunagiri K, Sekar B. OXA beta-lactamase-mediated carbapenem resistance in *Acinetobacter baumannii*. *Indian J Med Microbiol*. 2011;**29**(3):269-74.
 5. Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect*. 2006;**12**(9):826-36.
 6. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N. Diversity of carbapenem resistance mechanisms in *Acinetobacter baumannii* from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. *J Antimicrob Chemother*. 2009;**63**(4):641-7.
 7. Yang HY, Lee HJ, Suh JT, Lee KM. Outbreaks of imipenem resistant *Acinetobacter baumannii* producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. *Yonsei Med J*. 2009;**50**(6):764-70.
 8. Merino M, Acosta J, Poza M, Sanz F, Beceiro A, Chaves F, et al. OXA-24 carbapenemase gene flanked by XerC/XerD-like recombination sites in different plasmids from different *Acinetobacter* species isolated during a nosocomial outbreak. *Antimicrob Agents Chemother*. 2010;**54**(6):2724-7.
 9. Paton R, Miles RS, Hood J, Amyes SG, Miles RS, Amyes SG. ARI 1: beta-lactamase-mediated imipenem resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents*. 1993;**2**(2):81-7.
 10. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother*. 2010;**65**(2):233-8.
 11. D'Arezzo S, Principe L, Capone A, Petrosillo N, Petrucca A, Visca P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant *Acinetobacter baumannii* lineage causing multiple outbreaks in central Italy. *J Antimicrob Chemother*. 2011;**66**(1):54-61.
 12. Chen TL, Lee YT, Kuo SC, Hsueh PR, Chang FY, Siu LK, et al. Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAbal1 in carbapenem-resistant *Acinetobacter baumannii* isolates in Taiwan. *Antimicrob Agents Chemother*. 2010;**54**(11):4575-81.
 13. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement*. Wayne, PA: CLSI; 2011.
 14. Grundmann HJ, Towner KJ, Dijkshoorn L, Gerner-Smidt P, Maher M, Seifert H, et al. Multicenter study using standardized protocols and reagents for evaluation of reproducibility of PCR-based fingerprinting of *Acinetobacter* spp. *J Clin Microbiol*. 1997;**35**(12):3071-7.
 15. Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. *Iran J Microbiol*. 2011;**3**(2):68-74.
 16. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006;**44**(8):2974-6.
 17. Zander E, Nemeč A, Seifert H, Higgins PG. Association between beta-lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of *Acinetobacter baumannii* isolates. *J Clin Microbiol*. 2012;**50**(6):1900-4.
 18. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis*. 2008;**61**(4):274-8.
 19. Lee YT, Kuo SC, Chiang MC, Yang SP, Chen CP, Chen TL, et al. Emergence of carbapenem-resistant non-*baumannii* species of *Acinetobacter* harboring a blaOXA-51-like gene that is intrinsic to *A. baumannii*. *Antimicrob Agents Chemother*. 2012;**56**(2):1124-7.
 20. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A, et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of *Acinetobacter* spp.: co-existence with OXA-58 in multiple centres. *J Antimicrob Chemother*. 2006;**58**(3):537-42.
 21. Kock MM, Bellomo AN, Storm N, Ehlers MM. Prevalence of carbapenem resistance genes in *Acinetobacter baumannii* isolated from clinical specimens obtained from an academic hospital in South Africa: original research. *South Afr J Epidemiol Infect*. 2013;**28**(1):28-32.
 22. Akbari M, Niakian M, Taherikalani M., Feizabadi MM, Azadi NA, Soroush S. Rapid identification of Iranian *Acinetobacter baumannii* strains by single PCR assay using blaOxa-51-like carbapenemase and evaluation of the antimicrobial resistance profiles of the isolates. *Acta Microbiol Immunol Hung*. 2010;**57**(2):87-94.
 23. Karmostaji A, Najari Peerayeh S, Hatf Salமானian A. Distribution of OXA-Type Class D β-Lactamase Genes Among Nosocomial Multi Drug Resistant *Acinetobacter baumannii* Isolated in Tehran Hospitals. *Jundishapur J Microbiol*. 2013;**6**(5):e8219.
 24. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007;**51**(4):1530-3.
 25. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of *Acinetobacter baumannii*. *Emerg Infect Dis*. 2010;**16**(1):35-40.
 26. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD. Dissemination of multidrug-resistant *Acinetobacter baumannii* genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. *Int J Antimicrob Agents*. 2009;**34**(1):25-8.
 27. Goudarzi H, Douraghi M, Ghalavand Z, Goudarzi M. Assessment of antibiotic resistance pattern in *Acinetobacter baumannii* carrying bla oxa type genes isolated from hospitalized patients. *Novelty Biomed*. 2013;**1**(2):54-61.
 28. Nowak P, Paluchowska P, Budak A. Distribution of blaOXA genes among carbapenem-resistant *Acinetobacter baumannii* nosocomial strains in Poland. *New Microbiol*. 2012;**35**(3):317-25.
 29. Sadeghifard N, Ranjbar R, Zaeimi J. Antimicrobial susceptibility, plasmid profiles, and RAPD-PCR typing of *Acinetobacter* bacteria. *Asian Biomed*. 2011;**4**(6):901-11.
 30. Popova AV, Myakinina VP, Platonov ME, Volozhantsev NV. Molecular genetic characterization of multidrug-resistant *Acinetobacter baumannii* strains and assessment of their sensitivity to phage AP22. *Mol Gen Microbiol Virol*. 2012;**27**(4):154-9.